KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 6037 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Analysis of East Asia subgroup in Study 309/KEYNOTE-775: lenvatinib plus pembrolizumab versus treatment of physician's choice chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. PMID 38302725 · J Gynecol Oncol · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Decreasing polypharmacy in older adults with cancer: A pilot cluster-randomized trial protocol. PMID 38302299 · J Geriatr Oncol · 2024-Mar 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Trofinetide Treatment Demonstrates a Benefit Over Placebo for the Ability to Communicate in Rett Syndrome. PMID 38232652 · Pediatr Neurol · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials. PMID 38224918 · Radiother Oncol · 2024-Mar This is a review article discussing findings from two Phase III randomized surgical trials. It does not present original trial results with a drug-containing intervention, and the intervention is non-drug (surgical resection vs. sub-lobar resection).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of once-weekly insulin icodec in type 2 diabetes: A meta-analysis of ONWARDS phase 3 randomized controlled trials. PMID 38192022 · Diabetes Obes Metab · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. PMID 38177857 · Nat Med · 2024-Mar While the title references a primary result from a definitive Phase 3 RCT, the provided record is only the Author Correction (an erratum). The abstract is empty, so the core time-to-event endpoint signal cannot be verified. The metadata indicates it is not the original primary formal report. Therefore, eligibility cannot be established.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Asian participants' experience in phase 3/3b studies of long-acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96. PMID 38147871 · HIV Med · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
The osteoarthritis prevention study (TOPS) - A randomized controlled trial of diet and exercise to prevent Knee Osteoarthritis: Design and rationale. PMID 38144515 · Osteoarthr Cartil Open · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Author Correction: Cell-based versus corticosteroid injections for knee pain in osteoarthritis: a randomized phase 3 trial. PMID 38135824 · Nat Med · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty. PMID 38104480 · J Geriatr Oncol · 2024-Mar The record is a secondary analysis comparing frailty assessment methods using pooled data from Phase 3 trials. It does not report time-to-event efficacy outcomes for a drug intervention, is not an original trial report, and does not meet the criteria for inclusion as a definitive randomized controlled trial result.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. PMID 38101437 · Lancet Respir Med · 2024-Mar 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
A Multicenter Study Assessing the Real-World Use and Effectiveness of First-Line Chemotherapy Plus Immunotherapy in Advanced Small-Cell Lung Cancer (SCLC) Patients. PMID 38072729 · Clin Lung Cancer · 2024-Mar 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Diversity in Oncology Clinical Trials: Current Landscape for Industry-Sponsored Clinical Trials in Asia. PMID 38064162 · Oncol Ther · 2024-Mar This is an observational study comparing characteristics of clinical trials, not a report of an individual randomized trial with efficacy results. It does not contain a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier or HR) for a specific drug intervention.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. PMID 38062732 · Thyroid · 2024-Mar 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pharmacokinetics and pharmacodynamics of finerenone in patients with chronic kidney disease and type 2 diabetes: Insights based on FIGARO-DKD and FIDELIO-DKD. PMID 38037539 · Diabetes Obes Metab · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Pembrolizumab Versus Placebo as Post-nephrectomy Adjuvant Therapy for Clear Cell Renal Cell Carcinoma (KEYNOTE-564): 30-month Follow-up Analysis of a Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 3 Trial. PMID 37957046 · Eur Urol · 2024-Mar 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Correction: Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. PMID 37853068 · Pediatr Res · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
The MOTION study: a randomized, phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor. PMID 37593881 · Future Oncol · 2024-Mar This is a phase III randomized trial protocol for an oncology drug intervention. However, the abstract does not report any results, efficacy data, or time-to-event endpoints (like OS, PFS, etc.) from a completed analysis; it only describes the trial design.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States. PMID 37572861 · Clin Gastroenterol Hepatol · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Assessing the incidence and severity of drug adverse events: a Bayesian hierarchical cumulative logit model. PMID 37016726 · J Biopharm Stat · 2024-Mar 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Calcitriol in Sepsis-A Single-Centre Randomised Control Trial. PMID 38999389 · J Clin Med · 2024-Jun-29 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. PMID 38907288 · Trials · 2024-Jun-22 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. PMID 38906541 · BMJ · 2024-Jun-21 Cannot confirm a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) from the provided metadata (abstract is empty, no publication_types for results, no keywords/MESH indicating endpoints). The title suggests a clinical trial report, but without explicit endpoint information, eligibility is indeterminate.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treatment with intravenous alteplase in ischaemic stroke patients with onset time between 4.5 and 24 hours (HOPE): protocol for a randomised, controlled, multicentre study. PMID 37527920 · Stroke Vasc Neurol · 2024-Jun-21 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial. PMID 38890136 · BMJ Open · 2024-Jun-18 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Comprehensive Summary of Safety Data on Nirsevimab in Infants and Children from All Pivotal Randomized Clinical Trials. PMID 38921800 · Pathogens · 2024-Jun-13 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. PMID 38927498 · Biomedicines · 2024-Jun-11 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of tirofiban in patients with acute branch atheromatous disease-related stroke (BRANT): a protocol for a randomised controlled trial. PMID 38858147 · BMJ Open · 2024-Jun-10 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials. PMID 38851227 · BMJ Open · 2024-Jun-08 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study. PMID 38849943 · Trials · 2024-Jun-07 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature. PMID 38840219 · Arthritis Res Ther · 2024-Jun-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Validation of a Handheld 6-Lead Device for QT Interval Monitoring in Resource-Limited Settings. PMID 38848063 · JAMA Netw Open · 2024-Jun-03 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Patient-Reported Outcomes in Phase 3 Clinical Trials for Blood Cancers: A Systematic Review. PMID 38829615 · JAMA Netw Open · 2024-Jun-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia. PMID 38832425 · Haematologica · 2024-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. PMID 38722620 · JAMA Oncol · 2024-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Ghrelin for Neuroprotection in Post-Cardiac Arrest Coma: A Randomized Clinical Trial. PMID 38709502 · JAMA Neurol · 2024-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Design of OASIS 1 and 2: phase 3 clinical trials assessing the efficacy and safety of elinzanetant for the treatment of vasomotor symptoms associated with menopause. PMID 38564691 · Menopause · 2024-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Commentary on "Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study". PMID 38546431 · Dermatol Surg · 2024-Jun-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Pulmonary arterial hypertension treatment: an individual participant data network meta-analysis. PMID 38416633 · Eur Heart J · 2024-Jun-01 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
A novel application of XPO1 inhibition for the treatment of myelofibrosis. PMID 40454401 · Blood Neoplasia · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Devimistat plus chemotherapy vs chemotherapy alone for older relapsed or refractory patients with AML: results of the ARMADA trial. PMID 40454396 · Blood Neoplasia · 2024-Jun 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
A Risk-Difference Meta-Analysis for the Prophylactic Treatments of Chronic Migraine. PMID 39022494 · Cureus · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Corrigendum to "Design of a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of prucalopride in pediatric patients with functional constipation" [Contemp. Clin. Trials Commun. 33 (2023) 101144]. PMID 39007105 · Contemp Clin Trials Commun · 2024-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of l-oxiracetam and oxiracetam on memory and cognitive impairment in mild-to-moderate traumatic brain injury patients: Study protocol for a randomized controlled trial. PMID 38975302 · Aging Med (Milton) · 2024-Jun 方案论文未报告临床试验结果。
H
仅历史库存 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trial. PMID 38948164 · Lancet Reg Health West Pac · 2024-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Corrigendum to "Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials". PMID 38934595 · Cephalalgia · 2024-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease. PMID 38896547 · Expert Opin Pharmacother · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma. PMID 38860728 · Expert Opin Biol Ther · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. PMID 38849701 · Drugs · 2024-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Study protocol: A randomized, double-blind, placebo-controlled trial of isavuconazole prophylaxis for the prevention of covid-19-associated pulmonary aspergillosis. PMID 38832095 · Contemp Clin Trials Commun · 2024-Jun 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -